Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Merck TbkISX:MERK -0.52%78 EV-to-EBITDA is 3.10 as of Sep. 07, 2026, which is 62% below its 10-year median of 8.15. GuruFocus rates ISX:MERK with a GF Score™ of 78/100 and a GF Value™ of Rp4,925.19 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 726 Drug Manufacturers companies, PT Merck Tbk ranks better than 93.8% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PT Merck Tbk's enterprise value is Rp1,418,740 Mil.
PT Merck Tbk's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was Rp457,846 Mil. Therefore, PT Merck Tbk's EV-to-EBITDA for today is 3.10.
The historical rank and industry rank for PT Merck Tbk's EV-to-EBITDA or its related term are showing as below:
ISX:MERK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -170.21 Med: 8.15 Max: 92.88
Current: 3.1
During the past 13 years, the highest EV-to-EBITDA of PT Merck Tbk was 92.88. The lowest was -170.21. And the median was 8.15.
ISX:MERK's EV-to-EBITDA is ranked better than 93.8% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.56
vs ISX:MERK: 3.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Merck Tbk's PE Ratio (TTM) for today is calculated as:
PT Merck Tbk's share price for today is Rp3860.00.
PT Merck Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp742.654.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PT Merck Tbk's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:MERK vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Merck Tbk's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Merck Tbk EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Merck Tbk's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Merck Tbk's EV-to-EBITDA falls into.
PT Merck Tbk's current Enterprise Value is Rp1,418,740 Mil.
PT Merck Tbk's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp457,846 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Merck Tbk (ISX:MERK) has a EV-to-EBITDA of 3.10 as of Sep. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Merck Tbk. This is 62% below median its historical median of 8.15. According to the industry distribution chart, PT Merck Tbk ranks #45 out of 726 companies in the Drug Manufacturers industry, placing it in the top 6.2%.
Is PT Merck Tbk's EV-to-EBITDA too high?
PT Merck Tbk's current EV-to-EBITDA of 3.10 is 62% below median its 10-year median of 8.15. The Drug Manufacturers industry median EV-to-EBITDA is 13.56. PT Merck Tbk's value of 3.10 is 77.1% below this industry median. Based on the distribution chart, PT Merck Tbk ranks #45 out of 726 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Merck Tbk has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Merck Tbk's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Merck Tbk ranks #45 out of 726 companies for EV-to-EBITDA. This places PT Merck Tbk in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.56. PT Merck Tbk's value of 3.10 is 77.1% below this benchmark. While the company's 10-year median is 8.15 vs. the industry median of 13.56, PT Merck Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.56, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Merck Tbk's current EV-to-EBITDA of 3.10 is 77.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Merck Tbk. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Merck Tbk's current EV-to-EBITDA is 3.10, which is 62% below median its own 10-year median of 8.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Merck Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Merck Tbk (ISX:MERK) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp4,925.19, compared to a current price of Rp3,860.00 — trading 21.6% below its estimated fair value. The current EV-to-EBITDA is 3.10, which is 62% below median its 10-year median of 8.15 and 77.1% below the Drug Manufacturers industry median of 13.56. PT Merck Tbk's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PT Merck Tbk (ISX:MERK), the current EV-to-EBITDA is 3.10 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Merck Tbk (ISX:MERK) Overvalued in 2026?
Based on GuruFocus' analysis, PT Merck Tbk stock appears to be undervalued.
The current stock price of Rp3,860.00 is trading 21.6% below its estimated GF Value™ of Rp4,925.19.
GuruFocus considers PT Merck Tbk to be Modestly Undervalued.
Key valuation signals for ISX:MERK:
EV-to-EBITDA: 3.10 (62% below median its 10-year median of 8.15)
GF Value™: Rp4,925.19 vs. price of Rp3,860.00 (21.6% below fair value)
Industry Position: 77.1% below the Drug Manufacturers median (#45 of 726)
No single metric tells the full story. See the ISX:MERK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia. The company operates in three segments: Biopharma, Consumer Health, and Others. The company offers pharmaceutical and biological prescription medicines for colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, as well as thyroid disorders such as hypothyroidism.
78GF Score
Get the complete analysis for ISX:MERK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:MERK has been successfully added to your 
